designer491/iStock via Getty Images
- Corcept Therpeutics (CORT) has resubmitted an NDA for its Cushing’s syndrome candidate relacorilant.
- The resubmission includes new data analyses.
- The US FDA issued the company a Complete Response Letter in December saying it could not determine a favorable benefit-risk assessment